title: The effect of eicosapentaenoic acid on renal function and volume in patients with ADPKD.
abstract: BACKGROUND
  Soy protein ameliorates rat polycystic kidney disease with concomitant renal enrichment of omega3-polyunsaturated fatty acids. A study was conducted to examine the effects of eicosapentaenoic acids (EPA) on renal volume and function in patients with autosomal dominant polycystic kidney disease (ADPKD).
  
  
  METHODS
  Non-azotemic patients were randomized to either a control group (n = 20) or an EPA group (n = 21). EPA capsules (2.4 g/day) were administered in the EPA group for 2 years. Twenty-four hours of urine was collected for the creatinine clearance (Ccr) measurement every year. At baseline and 24 months, fatty acid compositions in erythrocytes were measured and computerized tomographies were obtained for calculation of renal volume by the modified ellipsoid and volumetric methods.
  
  
  RESULTS
  In the EPA group, the EPA concentration (1.80 +/- 0.99 versus 4.40 +/- 1.79 area%, P < 0.001) and the omega3/omega6 ratio in the erythrocyte increased, but docosahexaenoic acid (DHA) (6.76 +/- 1.19 versus 5.64 +/- 1.45 area%, P < 0.010) concentration decreased. Ccr decreased by 8.5 +/- 9.5 and 9.0 +/- 13.0 ml/min/1.73 m(2)/2 years in the control and EPA groups, respectively (NS). The increases in renal volume calculated by either method were not significantly different between the two groups.
  
  
  CONCLUSIONS
  A beneficial effect of EPA on renal function and kidney volume in ADPKD patients could not be confirmed in the present study. Administration of EPA with DHA supplementation and/or longer intervention might be necessary to demonstrate preventive effects of omega3-polyunsaturated fatty acids on progression of ADPKD.
authors: Department of Urology, Kyorin University School of Medicine, Mitaka, Tokyo 181-8611, Japan. ehigashi@kyorin-u.ac.jp
authors: Eiji
authors: E
authors: Higashihara
authors: Kikuo
authors: K
authors: Nutahara
authors: Shigeo
authors: S
authors: Horie
authors: Satoru
authors: S
authors: Muto
authors: Tatsuo
authors: T
authors: Hosoya
authors: Kazushige
authors: K
authors: Hanaoka
authors: Ken
authors: K
authors: Tuchiya
authors: Kouichi
authors: K
authors: Kamura
authors: Kenmei
authors: K
authors: Takaichi
authors: Yoshifumi
authors: Y
authors: Ubara
authors: Miho
authors: M
authors: Itomura
authors: Tomohito
authors: T
authors: Hamazaki
mesh_terms: D000293:Adolescent; D000328:Adult; D003404:Creatinine / Q000652:urine; D018450:Disease Progression; D015118:Eicosapentaenoic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D004912:Erythrocytes / Q000737:chemistry; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009929:Organ Size / Q000187:drug effects; D016891:Polycystic Kidney, Autosomal Dominant / Q000188:drug therapy / Q000503:physiopathology*; D011446:Prospective Studies; D055815:Young Adult
chemical_list: D015118:Eicosapentaenoic Acid; D003404:Creatinine